Cathie Wood’s ARK Invest executed a strategic portfolio rebalancing on Wednesday, March 25, reducing exposure to Meta and Roku while significantly increasing its position in healthcare artificial intelligence firm Tempus AI.
Meta Platforms, Inc., META
The investment management firm disposed of 3,578 Meta shares distributed across three distinct funds. Calculated against Wednesday’s closing price, the transaction value reached approximately $2.1 million. Following this divestment, the ARK Innovation ETF maintains a position of roughly 105,000 Meta shares, currently valued near $63 million — representing about 1% of total fund assets.
Meta experienced a tumultuous Wednesday marked by multiple significant developments. A jury delivered a verdict determining that both Meta and Google’s YouTube demonstrated negligence by operating platforms that caused harm to minors in a groundbreaking social media addiction lawsuit. Both technology giants indicated their intention to pursue appeals.
Simultaneously, Meta introduced an ambitious executive compensation structure targeting a 500% stock appreciation and a $9 trillion market capitalization by 2031. The company acknowledged to Barron’s that workforce reductions would affect several hundred staff members throughout its sales, recruitment, and virtual reality departments. Remarkably, despite this flurry of news, Meta’s stock price gained only 0.3% by market close.
ARK Invest also liquidated 95,090 Roku shares spanning its ARKK, ARKW, and ARKF funds, generating proceeds of approximately $9.1 million. This sale represents a continuation of selling activity, following a substantial Roku divestment executed on March 24.
Additional Wednesday disposals encompassed 30,174 Teradyne shares valued at roughly $9.7 million, along with 205,019 Bullish shares distributed across three ETFs totaling about $7.7 million. ARK has maintained a pattern of reducing its Bullish position throughout the preceding week.
Further sales activity included the disposal of 62,393 Kratos Defense shares and 27,647 Natera shares, generating proceeds of $4.8 million and $5.4 million respectively.
On the acquisition front, ARK’s primary focus centered on Tempus AI. The firm accumulated 84,939 shares via its ARKK and ARKG ETFs, deploying approximately $4.1 million in capital.
Tempus AI experienced a 4.2% decline on Wednesday and has retreated 21% year-to-date in 2026. ARK’s acquisition appears strategically timed as a value-buying opportunity during the pullback.
The ARK Innovation ETF currently maintains approximately 6.3 million Tempus AI shares with a market value exceeding $294 million. This position has ascended to the fund’s third-largest allocation, trailing only Tesla and Crispr Therapeutics, constituting roughly 5% of aggregate fund holdings.
Wednesday’s trading activity reflects an ongoing strategic shift within ARK’s portfolio management. The firm has systematically decreased allocations to Roku, Teradyne, and Bullish across multiple consecutive trading sessions.
Concurrently, ARK has been methodically expanding its Tempus AI exposure. Tempus AI operates as a healthcare technology enterprise leveraging artificial intelligence to enhance medical data analysis and oncology treatment protocols.
Supplementary purchases during the session included shares of Archer Aviation, Beam Therapeutics, and additional smaller positions.
The ARK Innovation ETF registered a 1.3% gain on Wednesday’s trading session.
The post ARK Invest Exits Meta (META) and Roku (ROKU) Positions While Loading Up on Tempus AI appeared first on Blockonomi.


